The Drug Enforcement Administration is the federal agency responsible for enforcing the controlled substances laws of the United States. It is the primary law enforcement body with jurisdiction over the Controlled Substances Act, and it is the agency most likely to appear at the door of a physician, pharmacist, or other registered practitioner whose prescribing practices have attracted federal attention.
The DEA was established in 1973 by President Nixon’s executive order consolidating several federal drug enforcement agencies into a single body within the Department of Justice. It operates domestic field divisions in every major metropolitan area in the United States, maintains foreign offices in more than sixty countries, and employs approximately ten thousand personnel including special agents, diversion investigators, and intelligence analysts. Its annual budget exceeds three billion dollars.
The DEA’s Dual Mandate
The DEA operates under a dual mandate that distinguishes it from most federal law enforcement agencies. It is simultaneously an enforcement agency and a regulatory one. On the enforcement side, the DEA investigates and prosecutes drug trafficking, drug conspiracy, and controlled substance distribution offenses through its criminal enforcement divisions. On the regulatory side, the DEA’s Diversion Control Division registers, monitors, and regulates the more than two million entities and individuals who are authorized to handle controlled substances under the Controlled Substances Act.
The regulatory function creates a relationship between the DEA and licensed practitioners, pharmacists, and healthcare entities that does not exist between the DEA and ordinary citizens. A physician who holds a DEA registration is a regulated entity subject to the DEA’s administrative authority, including the authority to inspect the registrant’s controlled substance records, to conduct compliance audits, and to seek the suspension or revocation of the registration without a criminal proceeding. The administrative enforcement mechanism is available to the DEA as an independent tool and is frequently deployed in advance of or alongside criminal investigation.
The Diversion Control Division
The Diversion Control Division is the component of the DEA that is most directly relevant to healthcare practitioners, pharmacists, and pharmaceutical industry participants. The Division maintains approximately nine hundred diversion investigators across more than seventy field offices. Its mission is to prevent, detect, and investigate the diversion of pharmaceutical controlled substances from legitimate medical, scientific, research, and industrial channels.
Diversion investigators are not special agents: they are not armed law enforcement officers in the criminal enforcement sense. They are regulatory investigators with the authority to inspect DEA registrants’ records, to conduct audits of controlled substance inventories, and to gather the administrative evidence that supports both civil DEA administrative proceedings and referrals to criminal investigation. An unannounced visit from a diversion investigator is a regulatory inspection. It is also often the first visible sign of an investigation that began with a referral from a prescription drug monitoring program, a complaint from a patient or pharmacy, or a data analytics flag generated by the DEA’s own systems.
Need Help With Your Case?
Don't face criminal charges alone. Our experienced defense attorneys are ready to fight for your rights and freedom.
- 100% Confidential
- Response Within 1 Hour
- No Obligation Consultation
Or call us directly:
(212) 300-5196Criminal Enforcement of Controlled Substance Violations
When diversion investigation develops evidence suggesting criminal conduct, the matter may be referred to the DEA’s special agent division for criminal investigation, to the Department of Justice for prosecution, or to the United States Attorney’s office in the relevant district. Criminal prosecutions of healthcare practitioners for controlled substance violations are handled by assistant United States attorneys, often in specialized health care fraud or narcotics units, with support from DEA special agents and, in complex cases, the DEA’s forensic laboratory and data analytics resources.
The criminal enforcement of opioid prescribing cases has been a priority within the DEA and the Department of Justice since the late 2000s, accelerating through the OxyContin crisis, the subsequent heroin transition, and the fentanyl epidemic that defines the current enforcement landscape. The resources directed at opioid prescribing enforcement are substantial, the prosecutorial priority is high, and the outcomes in contested cases reflect a government that has built significant institutional knowledge about how to try these cases.
The DEA’s regulatory authority means that a physician facing a diversion investigation is not only facing potential criminal charges. They are facing the administrative revocation of the registration that permits them to prescribe controlled substances at all. The administrative proceeding and the criminal proceeding can occur simultaneously, and the administrative outcome can arrive first, ending a medical career before any criminal charge is formally resolved.
Todd Spodek
Lead Attorney & Founder
Featured on Netflix's "Inventing Anna," Todd Spodek brings decades of high-stakes criminal defense experience. His aggressive approach has secured dismissals and acquittals in cases others deemed unwinnable.
The Immediate Suspension Order
Among the most significant tools in the DEA’s administrative arsenal is the immediate suspension order, which permits the DEA to suspend a practitioner’s DEA registration without prior notice when it finds that the public interest requires emergency action. The standard is whether continued registration constitutes an imminent danger to public health or safety. The order takes effect immediately upon service, eliminating the practitioner’s ability to prescribe controlled substances from the moment the order is served.
An immediate suspension order is not a conviction. It is an administrative determination, subject to challenge through the DEA’s administrative hearing process and ultimately through judicial review. But the practical effect of the order, on the day it is served, is the end of the practitioner’s ability to prescribe controlled substances until the administrative proceeding is resolved, which may take months or years. The practitioner who receives an immediate suspension order should retain counsel experienced in DEA administrative proceedings immediately, not after assessing whether the order is legally defensible.